BSTZ vs AGIO Comparison

BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.